AstraZeneca stock value falls by nearly £14bn after cancer drug trial results

The firm said it was too soon to say with statistical significance if patients using the drug could live longer than those on currently available treatments. Photograph: Phil Noble/Reuters

Nearly £14bn has been wiped off the stock market value of AstraZeneca over concerns that a new lung cancer drug may not be as successful as had been hoped.

Shares in the Anglo-Swedish pharmaceutical company closed down 8% on Monday after it published the first results from its phase 3 trial for datopotamab deruxtecan, making it the biggest faller among FTSE 100 companies.